Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 17, 2023

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions

Breast Cancer Female

Interventions

DRUG

Pyrotinib and Trastuzumab

Small and large molecules combined with chemotherapy for neoadjuvant treatment of HER2-positive breast cancer

Trial Locations (1)

RECRUITING

The First Affiliated Hospital of Fujan Medical University, Fuzhou

All Listed Sponsors

lead

Youzhi Zhu

OTHER